title: [The results and characteristics of the mupirocin (Bactroban) sanative treatment of intranasal Staphylococcus carriers in a large hospital].
abstract: The action of mupirocin as a nasal ointment (Bactroban) was studied on intranasal carriers of the hospital staphylococcal strains. The study included 37 medical workers from different and mainly problem units of the large general hospital. The tolerability of the ointment was good. After the Bactroban use no complications of the patients were recorded. The efficacy of Bacroban by the microbiological criteria in total amounted to 100 per cent. The eradication of methicillin resistant Staphylococcus aureus (MRSA) was observed in 93 per cent of the cases. A decrease of the level of the nasal passages dissemination by MRSA and methicillin resistant coagulase-negative staphylococci (MRSC) up to such low titers as 100 and 90 per cent was stated. No difference in the action of Bactroban on MRSA, MSSA and MRSC was noted. The bacteriological monitoring for 3 to 4 months revealed a change of the staphylococcal strains in 94 per cent of the cases, recolonization by the same staphylococcal strain in 19 per cent, recolonization by some another staphylococcal strains in 33 per cent and no recolonization in 14 per cent. A stable decrease of staphylococcal strains was possible with simultaneous Bactroban sanitation of all the bacterial carriers of the hospital or its isolated unit.
authors.affiliation: Municipal Clinical Hospital No. 7, Moscow.
authors.forename: E A
authors.initials: EA
authors.lastname: Lykova
authors.forename: L V
authors.initials: LV
authors.lastname: Eremina
authors.forename: G V
authors.initials: GV
authors.lastname: Sterkhova
authors.forename: S S
authors.initials: SS
authors.lastname: Kozyreva
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy* / Q000382:microbiology; D003428:Cross Infection / Q000517:prevention & control*; D006801:Humans; D008505:Medical Staff, Hospital; D008826:Microbial Sensitivity Tests; D016712:Mupirocin / Q000627:therapeutic use*; D009666:Nose / Q000382:microbiology; D009668:Nose Diseases / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects / Q000302:isolation & purification
chemical_list: D000900:Anti-Bacterial Agents; D016712:Mupirocin